Evidence map›Paper›PMID 36541551›Full record

ArticleNeuro-oncology2023

Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants.

Jennifer L Stundon, Heba Ijaz, Krutika S Gaonkar, Rebecca S Kaufman, Run Jin, Anastasios Karras, Zalman Vaksman, Jung Kim, Ryan J Corbett, Matthew R Lueder and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Mutant ATRX: pathogenesis of ATRX syndrome and cancer.Frontiers in molecular biosciences · 2024
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Jennifer L StundonDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Heba IjazDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Krutika S GaonkarCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Rebecca S KaufmanDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Run JinCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Anastasios KarrasDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Zalman VaksmanDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Jung KimDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland,USA.
Ryan J CorbettCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Matthew R LuederCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Daniel P MillerCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Yiran GuoCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Mariarita SantiDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Marilyn LiDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Gonzalo LopezDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.ORCID 0000-0002-5092-1284
Phillip B StormCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Adam C ResnickCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Angela J WaandersDivision of Hematology, Oncology, NeuroOncology, and Stem Cell Transplant, Ann & Robert H Lurie Children's Hospital of Chicago, Illinois,USA.
Suzanne P MacFarlandDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Douglas R StewartDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland,USA.
Sharon J DiskinDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Jo Lynne RokitaCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.ORCID 0000-0003-2171-3627
Kristina A ColeDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,USA.
Children's Hospital of Philadelphia · USNational Cancer Institute · USNorthwestern University · US

Funding

Data Analysis UnitU2CCA233285 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI HUNGER, STEPHEN PATRICK, TAN, KAI · 2018 to 2023
$13.2M
CANCER RESEARCH TRAINING PROGRAMT32CA009615 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Gregory L Beatty, MICHAEL D HOGARTY · 1988 to 2026
$10.4M
Pediatric Scholars ProgramK12HD043245 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI ST. GEME, JOSEPH W. · 2003 to 2022
$7.4M
Discovering the genetic basis of neuroblastoma initiation and progressionR03CA230366 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI DISKIN, SHARON · 2018 to 2019
$344k
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS R03 CA230366NCI NIH HHS T32 CA009615NCI NIH HHS U2C CA233285NICHD NIH HHS K12 HD043245NIH HHS U2C-CA233285
6 · The paper itself

Abstract

backgroundTo achieve replicative immortality, most cancers develop a telomere maintenance mechanism, such as reactivation of telomerase or alternative lengthening of telomeres (ALT). There are limited data on the prevalence and clinical significance of ALT in pediatric brain tumors, and ALT-directed therapy is not available.

methodsWe performed C-circle analysis (CCA) on 579 pediatric brain tumors that had corresponding tumor/normal whole genome sequencing through the Open Pediatric Brain Tumor Atlas (OpenPBTA). We detected ALT in 6.9% (n = 40/579) of these tumors and completed additional validation by ultrabright telomeric foci in situ on a subset of these tumors. We used CCA to validate TelomereHunter for computational prediction of ALT status and focus subsequent analyses on pediatric high-grade gliomas (pHGGs) Finally, we examined whether ALT is associated with recurrent somatic or germline alterations.

resultsALT is common in pHGGs (n = 24/63, 38.1%), but occurs infrequently in other pediatric brain tumors (<3%). Somatic ATRX mutations occur in 50% of ALT+ pHGGs and in 30% of ALT- pHGGs. Rare pathogenic germline variants in mismatch repair (MMR) genes are significantly associated with an increased occurrence of ALT.

conclusionsWe demonstrate that ATRX is mutated in only a subset of ALT+ pHGGs, suggesting other mechanisms of ATRX loss of function or alterations in other genes may be associated with the development of ALT in these patients. We show that germline variants in MMR are associated with the development of ALT in patients with pHGG.

Indexed as

Brain NeoplasmsGliomaChildDNA Mismatch RepairHumansMutationTelomereTelomere HomeostasisX-linked Nuclear ProteinATRX protein, humanX-linked Nuclear Proteinalternative lengthening of telomeresATRXmismatch repairpediatric brain tumorspHGGTelomere

Identifiers

PMID36541551
PMCPMC10326481
OpenAlexW4312065085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.